(Research.gov)
BioPontis Alliance, a hybrid investment fund and product development company in Raleigh, North Carolina, and global pharmaceutical company Pfizer Inc. agreed to collaborate on translational technology development supported by BioPontis. The companies announced the deal at the 2011 BIO International Convention in Washington, D.C.
BioPontis establishes research alliances with academic-research institutes, where BioPontis searches for advances that have potential to be translated into treatments for cancer, neurology, inflammation, and infectious diseases. The company provides direct investments out of its fund, and its scientists work with the academic-inventor scientists and a network of technology partners to validate and advance products toward pipelines of biopharmaceutical licensors.
BioPontis currently has agreements with a consortium of universities and research institutions, including New York University, Columbia University, Memorial Sloan-Kettering Cancer Center, University of Pennsylvania, University of North Carolina at Chapel Hill, University of Virginia, and University of Florida.
Under the agreement, Pfizer will provide guidance on the BioPontis product portfolio to help BioPontis ensure that its investments in particular development programs are in alignment with clinical needs and market demand. Pfizer will have the opportunity to provide BioPontis with scientific and medical advice on the design of experiments and the product profile needed for a product-development strategy. Pfizer will also have an opportunity to evaluate and license early-stage therapeutic opportunities.
Also at the BIO convention, Janssen Biotech Inc. in Horsham, Pennsylvania became a technology partner with BioPontis Alliance. Like the Pfizer deal, Janssen will advise BioPontis on its R&D strategy, and have access to evaluate and license early-stage therapeutic opportunities.
Read more: Pfizer Adds Mass. Institutions to Translational Network
* * *
RSS - Posts
You must be logged in to post a comment.